No-charge genetic testing for the acute hepatic porphyrias
Invitae and Alnylam have partnered to offer genetic testing at no charge for individuals who may carry a gene mutation known to be associated with the acute hepatic porphyrias (AHPs).
On average, it takes 15 years from symptom onset for a patient to receive a correct diagnosis of AHP.1 The Alnylam ActTM program was developed to reduce barriers to genetic testing and counseling in order to help people make more informed decisions about their health.
While Alnylam provides financial support for this program, tests and services are performed by independent third parties. Healthcare professionals must confirm that patients meet certain criteria to use the program. Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient identifiable information. Alnylam receives contact information for health care providers who use this program. Genetic testing is available in the U.S. and Canada. Genetic counseling is only available in the U.S. Healthcare professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any Alnylam product.